Aotai Biotech (688606.SH) disclosed the 2023 annual results report, and the company achieved a total operating revenue of 7.55...
According to Zhitong Finance App News, Aotai Biotech (688606.SH) revealed the 2023 annual performance report. The company achieved total operating revenue of 755 million yuan, down 77.73% from the same period last year; realized net profit attributable to shareholders of the parent company of 180 million yuan, a decrease of 84.80% over the same period last year; realized net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 146 million yuan, a decrease of 87.46% over the same period last year.
During the reporting period, the company's revenue and net profit declined significantly, mainly due to changes in domestic and international public health prevention and control policies, a sharp decline in global demand for COVID-19 antigen detection reagents, and a decline in sales revenue related to the company's COVID-19 antigen testing products. In 2023, the company continued to consolidate its first-mover R&D advantage in the industry and insisted on product innovation and market development, resulting in a 27.41% increase in sales revenue for the company's conventional products (excluding COVID-19 single-test products) over the same period last year.
